Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ, de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, Van Leuven F, Lucassen PJ. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci. 2006 Mar 29;26(13):3514-23. PubMed Abstract

  
Comments on Paper and Primary News
  Comment by:  Li-Huei Tsai
Submitted 8 April 2006  |  Permalink Posted 9 April 2006
  I recommend this paper

  Primary News: Mutant Tau Sharpens Wits of Young Mice

Comment by:  Andre Fischer
Submitted 10 April 2006  |  Permalink Posted 10 April 2006

In this study, Boekhoorn et al. investigated synaptic plasticity, learning, and memory in young versus aged tauP301L mice. They found that learning in the novel object paradigm was significantly better in young tauP301L mice when compared to a control group. In addition, long-term potentiation, which is commonly viewed as a molecular correlate for learning and memory, was found to be enhanced in tauP301L mutant mice when measured in the perforant path-dentate gyrus pathway of the hippocampus. These findings are very surprising, since the tauP301L mutation is linked to frontotemporal dementia with parkinsonism (FTDP-17) in humans, and tau pathology is one of the hallmarks of the pathogenesis of Alzheimer disease (AD). Consistently inducible overexpression of tauP301L in the forebrain of mice causes severe cognitive deficits in aged mice (Santacruz et al., 2005).

Although the mechanism by which tauP301L causes facilitated memory in young mice is not clear (Boekhoorn et al. ruled out morphological changes or neurogenesis in the hippocampus as underlying mechanisms), these...  Read more


  Primary News: Mutant Tau Sharpens Wits of Young Mice

Comment by:  Jurgen Goetz, ARF Advisor
Submitted 10 April 2006  |  Permalink Posted 10 April 2006

This study of a beneficial effect of tau as shown by improved long-term potentiation, in the absence of tau hyperphosphorylation, demonstrates that tau mutations, such as P301L, are not per se causing cognitive decline. As this research group has in the past also generated human wild-type tau transgenic mice without carrying mutations, it would be an interesting follow-up study to repeat the electrophysiology, Golgi stainings, and the analysis of neurogenesis with these mice to determine whether higher wild-type tau levels would lead to even more improvement.

View all comments by Jurgen Goetz

  Comment by:  Anne Fagan, ARF Advisor
Submitted 13 April 2006  |  Permalink Posted 13 April 2006
  I recommend this paper

  Primary News: Mutant Tau Sharpens Wits of Young Mice

Comment by:  Akihiko Takashima, ARF Advisor
Submitted 14 April 2006  |  Permalink Posted 14 April 2006

Boekhoorn and colleagues indicated that their P301L tau transgenic mice showed higher LTP and memory performance when they are young—before NFTs and hyperphosphorylation have occurred yet. But Mandelkow’s group found that tau overexpression inhibits the anterograde transport along microtubules by obstructing kinesin movement; their result was rather opposite. If P301L mutant tau binds to the microtubule, axonal transport should be inhibited, leading to synaptic dysfunction. However, young Tg mice exhibited “improvement” of synaptic function compare to non-Tg mice. Tau overexpression may, therefore, have two effects. On the one hand, it improves synaptic function in young mice, and on the other, it causes neurodegeneration through hyperphosphorylation and aggregation in cytoplasm of older animals. In the case of human brain, tau never gets overexpressed during the entire lifespan. Tau does accumulate in the case of FTDP-17, where it induces NFTs and neuronal loss without overexpression. Therefore, we need to clarify the effects of tau mutations, rather than overexpression, on...  Read more
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

Tau-P301L transgenic mice in the FVB/N genetic background were used in this study.

Immunohistochemistry (IHC) for phosphorylation-independent human tau with monoclonal antibody (mAb) (HT7, 1:10,000; Innogenetics, Gent, Belgium) and for the specific phospho-epitope Ser(P)396/Ser(P)404(AD2, 1:1000; A. Delacourte), Thr(P)231 (AT180, 1:250; Innogenetics), and Ser(P)202/Thr(P)205 ((AT8, 1:1000; Innogenetics)

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad